Last updated: August 6, 2026
Efavirenz/emtricitabine/tenofovir disoproxil fumarate, marketed in the United States as Atripla, moved from a major HIV franchise to a mature generic antiretroviral product. Gilead Sciences and Bristol-Myers Squibb commercialized Atripla after FDA approval in 2006. Its market position weakened after 2015 as integrase inhibitor regimens replaced efavirenz-based therapy, generic versions entered, and public-health purchasers prioritized lower-cost alternatives. Atripla’s branded U.S. sales fell from approximately $3.5 billion in 2014 to less than $1 billion by 2019, with the decline continuing as generic substitution expanded.[1][2]
The product remains clinically relevant in some low- and middle-income markets, but its commercial profile is now defined by generic competition, procurement pricing and residual demand rather than premium branded pricing.
What is Atripla and how does the fixed-dose combination work?
Atripla combines three antiretroviral agents in one once-daily tablet:
| Component |
Drug class |
Primary function |
| Efavirenz |
Non-nucleoside reverse transcriptase inhibitor |
Inhibits HIV-1 reverse transcriptase |
| Emtricitabine |
Nucleoside reverse transcriptase inhibitor |
Inhibits viral DNA synthesis |
| Tenofovir disoproxil fumarate |
Nucleotide reverse transcriptase inhibitor |
Inhibits viral DNA synthesis |
The approved tablet contains efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg. FDA approved Atripla in July 2006 for treatment of HIV-1 infection in adults and adolescents weighing at least 40 kilograms.[3]
Atripla’s commercial value came from simplifying treatment into a single daily tablet. Its clinical limitations include central nervous system adverse effects associated with efavirenz, renal and bone safety concerns associated with tenofovir disoproxil fumarate, and a higher resistance risk than many newer integrase inhibitor-based regimens.
How did Atripla’s market position change over time?
Atripla was one of the largest HIV products globally during the late 2000s and early 2010s. It benefited from single-tablet convenience, strong physician familiarity and rapid adoption in treatment-naive patients.
Its market position weakened for four reasons:
- Newer single-tablet regimens offered improved tolerability and fewer efavirenz-related neuropsychiatric effects.
- Integrase strand transfer inhibitor regimens became preferred in U.S. treatment guidelines.
- Generic efavirenz, emtricitabine and tenofovir disoproxil fumarate products reduced price.
- HIV treatment shifted toward tenofovir alafenamide and integrase inhibitor combinations, including Biktarvy, Genvoya, Stribild and Triumeq.
The U.S. Department of Health and Human Services guidelines no longer position efavirenz-based therapy as a preferred initial regimen for most adults. Recommended initial therapy generally uses an integrase inhibitor, such as bictegravir or dolutegravir, combined with two nucleoside reverse transcriptase inhibitors.[4]
Atripla commercial timeline
| Year |
Event |
Commercial effect |
| 2006 |
FDA approval of Atripla |
Established the first widely used single-tablet HIV regimen in the United States |
| 2007-2013 |
Rapid adoption |
High branded pricing and strong treatment initiation demand |
| 2014 |
Peak reported Gilead sales of approximately $3.5 billion |
Franchise reached maturity |
| 2015-2017 |
Shift toward newer HIV regimens |
Atripla sales declined materially |
| 2017-2019 |
Generic competition expanded |
Pricing and prescription share deteriorated |
| 2020 onward |
Mature generic market |
Branded Atripla became a residual product |
| Current market |
Primarily generic and public-sector demand |
Low strategic value as a branded growth asset |
What were Atripla’s peak sales and financial trajectory?
Atripla generated its highest reported sales in the middle of the 2010s. Gilead reported approximately $3.5 billion in Atripla product sales in 2014. Sales then declined each year as patients moved to newer regimens and generic alternatives became available.
| Fiscal year |
Approximate Gilead Atripla sales |
Main driver |
| 2014 |
$3.5 billion |
Mature branded franchise |
| 2015 |
$3.2 billion |
Early treatment migration |
| 2016 |
$2.3 billion |
Stronger uptake of newer regimens |
| 2017 |
$1.6 billion |
Continued regimen switching and generic pressure |
| 2018 |
$1.1 billion |
Broad erosion of branded demand |
| 2019 |
Less than $1.0 billion |
Mature product decline |
| 2020 onward |
Not separately material in public reporting |
Genericization and portfolio reclassification |
The figures are rounded and reflect Gilead’s reported product sales. They should not be interpreted as total global market revenue, because Atripla was commercialized through arrangements involving Gilead and Bristol-Myers Squibb, and regional revenue recognition varied.[1][2]
What caused the decline in Atripla revenue?
The principal factor was therapeutic substitution, not a sudden loss of HIV demand. Patients continued to require lifelong treatment, but the treatment mix changed.
Gilead’s newer products captured patients who would previously have started or remained on Atripla. Biktarvy, approved in 2018, became a major commercial replacement because it combined bictegravir, emtricitabine and tenofovir alafenamide in a once-daily tablet. Tenofovir alafenamide was positioned as having improved renal and bone safety relative to tenofovir disoproxil fumarate, although product selection depends on patient characteristics and clinical guidelines.
Atripla also lost pricing power. Once the active ingredients and relevant combination claims became available to generic manufacturers, the product shifted from a differentiated branded therapy to a procurement-driven antiretroviral.
When did Atripla lose exclusivity and when did generic entry begin?
Atripla’s effective U.S. market exclusivity ended in stages rather than on one date. The relevant barriers included patents covering the individual active ingredients, combination products, regulatory exclusivity and litigation or settlement terms.
The commercial loss of exclusivity occurred around the late 2010s and early 2020s. Generic efavirenz/emtricitabine/tenofovir disoproxil fumarate products were approved or introduced as the principal U.S. patents and regulatory barriers expired or were resolved.
What patents protected efavirenz, emtricitabine and tenofovir disoproxil fumarate?
The patent estate included several layers:
| Patent layer |
Protected subject matter |
Strategic importance |
| Efavirenz compound patents |
Efavirenz molecule and related chemical matter |
Covered the NNRTI active ingredient |
| Emtricitabine compound patents |
Emtricitabine and nucleoside analog chemistry |
Covered one NRTI component |
| Tenofovir prodrug patents |
Tenofovir disoproxil and fumarate salt forms |
Covered the orally useful prodrug |
| Combination patents |
Fixed-dose combinations containing the three agents |
Protected Atripla’s tablet architecture |
| Manufacturing and formulation patents |
Processes, salts, dosage forms and pharmaceutical compositions |
Created secondary barriers but had limited long-term durability |
| Regulatory exclusivity |
New-drug approval and pediatric exclusivity |
Delayed certain generic approvals independently of patents |
The Orange Book identified patents associated with Atripla and its active ingredients. Those listings included patents held or licensed by Gilead and Bristol-Myers Squibb and were subject to expiration, certification and litigation analysis under the Abbreviated New Drug Application pathway.[5]
The principal active-ingredient and combination barriers were generally exhausted by the early 2020s. Patent expiry dates could differ by jurisdiction, patent family, pediatric extensions, terminal disclaimers and settlement provisions. The practical result was the same: branded Atripla no longer had the patent-based pricing protection that supported its peak revenue.
Which companies challenged Atripla patents through Paragraph IV filings?
Generic pharmaceutical companies typically challenged listed Atripla patents through Paragraph IV certifications or pursued approval after patent expiration. The competitive field included large generic manufacturers with HIV portfolios, including Teva Pharmaceuticals, Mylan, Cipla, Lupin, Sun Pharmaceutical and other suppliers active in antiretroviral procurement.
Paragraph IV risk centered on whether the generic product infringed listed combination or formulation patents and whether those patents were valid and enforceable. The business value of a successful first-filer position was limited by the rapid commoditization of HIV products, particularly outside the U.S. market.
Atripla’s generic challenge profile differed from that of a small-molecule product with a single dominant composition patent. Its three active ingredients had distinct development histories and patent families. A generic applicant could pursue a fixed-dose combination while separately managing patents covering the active ingredients, processes and dosage form.
What is the Orange Book status of Atripla?
Atripla was approved under NDA 021937. The FDA Orange Book records the approved drug, dosage form, strength and applicable patent information.[3][5]
The relevant regulatory facts are:
- Atripla is a small-molecule, fixed-dose combination tablet.
- It is not a biologic and does not create biosimilar litigation risk.
- Generic competition proceeds through the ANDA pathway, not the biosimilar pathway.
- Orange Book patent listings do not guarantee enforceability or a specific market-exclusivity date.
- Generic applicants may file Paragraph IV certifications against listed patents.
- Approval timing can depend on patent litigation, settlement agreements, pediatric exclusivity and FDA review.
The product’s regulatory status is therefore materially different from that of a biologic HIV therapy. No biosimilar framework applies to efavirenz/emtricitabine/tenofovir disoproxil fumarate.
What generic launch scenarios exist for Atripla?
The U.S. generic market has three principal launch scenarios.
Multiple generic suppliers
This is the most likely long-term structure for a mature fixed-dose antiretroviral. Several manufacturers can supply the same active ingredients, pushing prices toward manufacturing and procurement economics.
Limited supplier competition
If only a small number of manufacturers maintain FDA-approved facilities, supply interruptions or quality events can temporarily increase prices. HIV procurement programs often manage this risk through framework contracts, dual sourcing and inventory requirements.
Public-sector tender dominance
Outside the United States, national programs, the Global Fund and PEPFAR can determine effective pricing. Large-volume tenders create low unit prices but may support stable demand for manufacturers with reliable regulatory and manufacturing capacity.
The product does not have a credible branded relaunch pathway absent a new formulation, a new indication or a major supply disruption. Its clinical differentiation has eroded too substantially.
What formulation patents protect efavirenz/emtricitabine/tenofovir disoproxil fumarate?
Formulation protection focused on the ability to combine three chemically different agents in a stable oral dosage form. Relevant technical issues included:
- tablet compression and excipient selection;
- moisture and chemical stability;
- dissolution profiles;
- particle size and blending;
- manufacturing process controls;
- fixed-dose uniformity;
- packaging and shelf life.
These patents could delay or complicate generic development, but formulation patents generally had lower long-term strategic value than composition patents. A generic manufacturer could challenge validity, design around claim limitations or develop a different excipient system while preserving bioequivalence.
Manufacturing remains a practical barrier even after patent expiry. Antiretroviral suppliers need validated processes, reliable active pharmaceutical ingredient sources, FDA or other regulatory approvals, and the ability to meet large public-sector orders at low margins.
What method-of-use patents affect Atripla?
Atripla’s principal commercial use was treatment of HIV-1 infection. Method-of-use patents could cover specific treatment populations, dosing approaches or combinations with other antiretrovirals. Their commercial impact was narrower than composition and fixed-dose combination patents because the core product had a broad treatment indication.
Method-of-use patents also face enforcement limits in generic substitution. A generic applicant can use a Section VIII statement or omit a patented indication where the regulatory pathway permits. The practical value of method-of-use patents depends on whether the patented indication represents a material share of prescriptions and whether pharmacy substitution laws allow the generic to reach those patients.
How does Atripla compare with Biktarvy and other competing HIV regimens?
| Product |
Active ingredients |
Core differentiation |
Commercial position |
| Atripla |
Efavirenz/emtricitabine/TDF |
Early once-daily single-tablet regimen |
Mature generic product |
| Biktarvy |
Bictegravir/emtricitabine/TAF |
Integrase-based efficacy and simplified dosing |
Major branded growth franchise |
| Genvoya |
Elvitegravir/cobicistat/emtricitabine/TAF |
Single-tablet integrase regimen |
Mature branded product |
| Stribild |
Elvitegravir/cobicistat/emtricitabine/TDF |
Earlier integrase single-tablet regimen |
Declining and largely displaced |
| Triumeq |
Dolutegravir/abacavir/lamivudine |
Integrase-based single-tablet option |
Established but constrained by abacavir considerations |
| Generic TDF/FTC/EFV |
Same three active ingredients as Atripla |
Low-cost access |
Public-sector and price-sensitive demand |
Biktarvy has the strongest direct commercial comparison because it preserves the single-tablet format while replacing efavirenz and TDF with bictegravir and TAF. Atripla retains relevance where price is more important than newer safety and tolerability characteristics.
What licensing deals affected Atripla economics?
Atripla was developed and commercialized through a collaboration between Gilead and Bristol-Myers Squibb. The arrangement combined Gilead’s nucleotide and nucleoside reverse transcriptase inhibitor portfolio with Bristol-Myers Squibb’s efavirenz franchise.
The economic structure involved regional commercialization rights, manufacturing responsibilities and intercompany payments. Gilead recorded significant Atripla sales and paid contractual amounts associated with Bristol-Myers Squibb’s rights. These arrangements reduced the amount of revenue retained by a single company compared with a wholly owned product.
The collaboration also affected lifecycle management. Gilead had incentives to shift patients from Atripla to newer internally controlled regimens, while Bristol-Myers Squibb’s strategic interest was linked to its broader HIV portfolio and efavirenz economics.
What patent litigation and settlement issues affected Atripla?
Atripla-related litigation followed the standard small-molecule generic model:
- generic ANDA filings;
- Paragraph IV challenges to listed patents;
- Hatch-Waxman patent litigation;
- potential 180-day first-filer exclusivity;
- settlement agreements governing launch timing;
- patent expiration or license-based entry.
The commercial effect of a settlement depends on the agreed launch date, authorized generic rights, royalty structure and whether the settlement permits entry before all listed patents expire. Such agreements can create a controlled erosion curve rather than an immediate loss of sales.
For Atripla, the major strategic issue was cumulative erosion. Even a delayed generic launch could not restore the product’s former market position because newer regimens had already taken substantial share.
What is the global market outlook for efavirenz/emtricitabine/tenofovir disoproxil fumarate?
The global outlook is divided by market.
In high-income markets, demand is declining. Treatment guidelines favor integrase inhibitor regimens, and prescribers increasingly avoid efavirenz because of neuropsychiatric adverse effects, drug interactions and resistance considerations.
In low- and middle-income markets, the product can retain demand because:
- it is inexpensive;
- it is available from multiple generic manufacturers;
- it has established procurement and clinical infrastructure;
- it can be supplied through large HIV treatment programs;
- physicians and public-health systems have extensive experience with the regimen.
WHO treatment guidance has moved toward dolutegravir-based regimens, including tenofovir-based combinations, because of efficacy, tolerability and resistance advantages.[6] That shift limits long-term growth for efavirenz-based combinations even where Atripla-equivalent products remain commercially available.
How strong is the patent estate for Atripla today?
The current patent estate is weak as a premium commercial defense. The product’s foundational composition and combination protections have largely expired or reached the end of their practical life in major markets.
Patent strength can still vary by country because of:
- different national filing dates;
- patent-term adjustments;
- supplementary protection certificates;
- pediatric extensions;
- local validity decisions;
- compulsory licensing rules;
- regulatory exclusivity differences.
The remaining barriers are more likely to be operational than patent-based. Manufacturing compliance, API sourcing, quality systems, tender access and regulatory maintenance now determine competitive success.
What revenue exposure remains for manufacturers?
Atripla has low strategic revenue exposure for originator companies but can remain meaningful for generic suppliers with low-cost manufacturing and public-sector contracts.
| Stakeholder |
Current economic exposure |
| Gilead Sciences |
Historical revenue decline; limited current branded growth contribution |
| Bristol-Myers Squibb |
Historical royalty and collaboration economics; no major current growth thesis |
| Generic manufacturers |
Low-margin volume opportunity |
| Public procurement agencies |
Cost-saving opportunity but supply-continuity risk |
| API suppliers |
Commodity-volume demand for three established ingredients |
| Investors |
Limited originator upside; potential generic supply-chain exposure |
The product should be valued as a mature, declining asset rather than a protected pharmaceutical franchise. Forecasts based on peak Atripla sales would materially overstate current commercial potential.
Key Takeaways
- Atripla is the principal branded product for efavirenz/emtricitabine/tenofovir disoproxil fumarate.
- FDA approved the fixed-dose tablet in 2006 under NDA 021937.
- Gilead’s reported Atripla sales peaked at approximately $3.5 billion in 2014.
- Revenue declined as patients moved to integrase inhibitor and tenofovir alafenamide regimens.
- Generic competition and patent expiry eliminated most branded pricing power by the early 2020s.
- The product has no biosimilar risk because it is a small-molecule drug.
- Current demand is concentrated in generic, price-sensitive and public-sector markets.
- Manufacturing reliability, procurement access and low-cost supply now matter more than patent protection.
- Biktarvy is the clearest commercial successor in the single-tablet HIV market.
- Atripla is no longer a credible branded growth asset, but generic demand can remain durable in selected global markets.
FAQs About Atripla Market Dynamics and Exclusivity
Is Atripla still sold in the United States?
Atripla may remain available through branded and generic channels, but U.S. utilization is substantially lower than during its peak commercial period. Generic efavirenz/emtricitabine/tenofovir disoproxil fumarate products are the principal competitive threat.
Is efavirenz/emtricitabine/tenofovir disoproxil fumarate recommended as first-line HIV therapy?
It is generally not a preferred first-line regimen in current U.S. guidelines. Integrase inhibitor-based regimens are usually preferred because of efficacy, tolerability and resistance considerations.[4]
Can a company obtain a biosimilar approval for Atripla?
No. Atripla is a small-molecule fixed-dose combination tablet. Competitors use the ANDA pathway for generic approval rather than the abbreviated biologics license application pathway used for biosimilars.
Does Atripla have pediatric exclusivity?
FDA regulatory exclusivity and patent-term extensions can affect particular products and time periods. The current commercial impact is limited because the core product faces generic competition and guideline-driven substitution.
Which product replaced Atripla commercially?
Biktarvy is the most direct commercial successor within Gilead’s single-tablet HIV portfolio. It uses bictegravir, emtricitabine and tenofovir alafenamide and reflects the market shift away from efavirenz and tenofovir disoproxil fumarate.
References
- Gilead Sciences, Inc. (2015). 2014 annual report. Gilead Sciences.
- Gilead Sciences, Inc. (2020). 2019 annual report. Gilead Sciences.
- U.S. Food and Drug Administration. (2006). Atripla prescribing information. FDA.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. U.S. Department of Health and Human Services.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
- World Health Organization. (2021). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring. WHO.
